Critchley J A, Ungar A
University Department of Clinical Pharmacology, Royal Infirmary, Edinburgh, Scotland.
Med Toxicol Adverse Drug Exp. 1989 Jan-Feb;4(1):32-45. doi: 10.1007/BF03259901.
Although many cases of beta-adrenoceptor antagonist (beta-blocker) poisoning are uneventful, a proportion develop serious and sometimes fatal cardiovascular system depression with severe hypotension. As beta-adrenergic tone is not essential for cardiovascular function in health, there is no physiological reason why total beta-adrenoceptor blockade should have serious consequences in the resting individual. The toxic actions of beta-blockers appear to be related to properties such as membrane depressant activity and possibly due to actions on beta-adrenoceptors distinct from those in the cardiovascular system. Most reports of serious adverse effects following overdosage concern beta-blockers with significant membrane depressant activity, and in particular propranolol and oxprenolol, with which progressive heart block and bradycardia are features. Sotalol toxicity, with its unique electrophysiological action, is a special case. Animal experiments confirm that beta-blockers with membrane depressant activity are more toxic than the newer more selective ones, such as atenolol and nadolol. However, experimental models also reveal that artificial ventilation markedly reduces the toxicity of all beta-blockers tested, suggesting a respiratory depressant action with very high doses. Treatment of serious overdosage in man should include maintenance of adequate ventilation. High dose intravenous glucagon is recommended, because its inotropic action depends on direct stimulation of adenylate cyclase. beta-Agonists such as isoprenaline (isoproterenol) or prenalterol may be effective, but the nature of agonist-competitive antagonist interactions may necessitate the use of unrealistically large doses to overcome very high tissue beta-blocker concentrations.
虽然许多β-肾上腺素能受体拮抗剂(β受体阻滞剂)中毒病例并无大碍,但一部分患者会出现严重的、有时甚至是致命的心血管系统抑制,并伴有严重低血压。由于β-肾上腺素能张力在健康状态下对心血管功能并非必不可少,所以从生理学角度讲,完全的β-肾上腺素能受体阻滞在静息个体中不应产生严重后果。β受体阻滞剂的毒性作用似乎与膜抑制活性等特性有关,也可能与作用于不同于心血管系统中的β-肾上腺素能受体的作用有关。大多数关于过量用药后严重不良反应的报道都涉及具有显著膜抑制活性的β受体阻滞剂,尤其是普萘洛尔和氧烯洛尔,它们的特点是会出现进行性心脏传导阻滞和心动过缓。索他洛尔因其独特的电生理作用,毒性情况较为特殊。动物实验证实,具有膜抑制活性的β受体阻滞剂比新型的、更具选择性的β受体阻滞剂(如阿替洛尔和纳多洛尔)毒性更大。然而,实验模型也表明,人工通气可显著降低所有受试β受体阻滞剂的毒性,这表明在极高剂量下会有呼吸抑制作用。对人类严重过量用药的治疗应包括维持充分通气。建议使用高剂量静脉注射胰高血糖素,因为其正性肌力作用依赖于对腺苷酸环化酶的直接刺激。诸如异丙肾上腺素或丙萘洛尔等β激动剂可能有效,但激动剂 - 竞争性拮抗剂相互作用的性质可能需要使用不切实际的大剂量药物来克服极高的组织β受体阻滞剂浓度。